Articularis Rheumatology Network

Trio Health and American Rheumatology Network Create New National Rheumatology Data Registry

Originally published on PRNewsWire.com WASHINGTON, Oct. 8, 2019 /PRNewswire/ — Trio Health, a leading provider of real-time data on real-world patients, today announced the creation of the nation’s first rheumatology registry, in partnership with American Rheumatology Network (ARN), that combines pharmacy dispensing data with electronic medical records (EMR) to provide unparalleled real-world insights into patient experiences and …

Trio Health and American Rheumatology Network Create New National Rheumatology Data Registry Read More »

ARN Physician Featured In Recent Article: Paying for Rheumatology Care is Complex

Originally published in Rheumatology Network The price of a medication can be a significant factor in poor adherence to treatment, and few other specialties have higher medication prices than rheumatology. How can rheumatologists help their patients navigate the system so that they can get the best medication at the best price? In the current U.S. …

ARN Physician Featured In Recent Article: Paying for Rheumatology Care is Complex Read More »

American Rheumatology Network, Building Something Better in Rheumatology

by Colin Edgerton, MD Articularis Rheumatology Network is announcing a name change to American Rheumatology Network (ARN). This is a coming of age moment for a network that has grown quickly to over 200 private practice rheumatologists across the country in only 8 months. American Rheumatology Network is a physician owned and led collaborative group …

American Rheumatology Network, Building Something Better in Rheumatology Read More »

Incorporating the Pharmacist into the Rheumatology Practice

Originally published in Rheumatology Network Better treatment outcomes have been documented in studies when physicians and pharmacists work together. During last year’s American College of Rheumatology’s annual meeting, Irvin Huang of the Boise VA Medical Center in Idaho, presented a small study of a  pharmacist-managed titration program in which gout patients achieved significantly lower serum uric acid …

Incorporating the Pharmacist into the Rheumatology Practice Read More »

ACR’s Recommendations for Controlling Drug Costs, Improving Outcomes

Originally published in Rheumatology Network Affordability is a leading cause of drug abandonment among rheumatology patients. Out-of-pocket costs can be substantial. For example, rheumatoid arthritis patients pay $5,471 in annual out-of-pocket costs for Humira, according to a report issued by the Kaiser Family Foundation in February. Back in April, the American College of Rheumatology issued a …

ACR’s Recommendations for Controlling Drug Costs, Improving Outcomes Read More »

We’re Exhibiting at National Organization of Rheumatology Managers

ARN’s CEO Ray Waldrup is looking forward to exhibiting at the NORM 2019 conference in a couple of days! Stop by Booth 3 for more information about how ARN GPO connects independent rheumatology practices across the nation to support one another in best practices, improve patient access and physician autonomy through value-based treatment pathways and …

We’re Exhibiting at National Organization of Rheumatology Managers Read More »

How One Rheumatology Practice Bolstered Uptake Of Biosimilar Infliximab

Originally published in Biosimilar Development by Anna Rose Welch, Editor It never ceases to excite me when I hear that some organization, hospital, or clinic has found a way to bring biosimilars to its patients — regardless of all the noise happening in the industry today. Though I imagine there are more patients being treated …

How One Rheumatology Practice Bolstered Uptake Of Biosimilar Infliximab Read More »

“Not So Different”: How a Value-Based Pathway Led to Increased Biosimilar Use

Originally published in the The Center For Biosimilars Web Site It’s no secret that biosimilars that treat inflammatory diseases have struggled to gain ground in the United States, with few products launched relative to those approved, low uptake of the products that are available, and formulary restrictions that sometimes favor branded biologics over biosimilar options. …

“Not So Different”: How a Value-Based Pathway Led to Increased Biosimilar Use Read More »

Why This Biosimilar Initiative In Rheumatology Is One To Watch

Originally published in Biosimilar Development by Anna Rose Welch, Editor Generally speaking, when it comes to fixing or advancing the U.S. healthcare system, it’s easier said than done. Look no further than the endless slew of proposed legislation that has, more often than not, been struck down in recent months. While in the EU, it’s …

Why This Biosimilar Initiative In Rheumatology Is One To Watch Read More »

Scroll to Top